Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

CD1a promotes systemic manifestations of skin inflammation

Hardman, Clare S., Chen, Yi-Ling, Wegrecki, Marcin, Ng, Soo Weei, Murren, Robert, Mangat, Davinderpreet, Silva, John-Paul, Munro, Rebecca, Chan, Win Yan, O’Dowd, Victoria, Doyle, Carl, Mori, Prashant, Popplewell, Andy, Rossjohn, Jamie ORCID: https://orcid.org/0000-0002-2020-7522, Lightwood, Daniel and Ogg, Graham S. 2022. CD1a promotes systemic manifestations of skin inflammation. Nature Communications 13 , 7535. 10.1038/s41467-022-35071-1

[thumbnail of 41467_2022_Article_35071.pdf] PDF - Published Version
Available under License Creative Commons Attribution.

Download (3MB)
[thumbnail of 41467_2022_35071_MOESM1_ESM.pdf] PDF - Supplemental Material
Available under License Creative Commons Attribution.

Download (3MB)

Abstract

Inflammatory skin conditions are increasingly recognised as being associated with systemic inflammation. The mechanisms connecting the cutaneous and systemic disease are not well understood. CD1a is a virtually monomorphic major histocompatibility complex (MHC) class I-like molecule, highly expressed by skin and mucosal Langerhans cells, and presents lipid antigens to T-cells. Here we show an important role for CD1a in linking cutaneous and systemic inflammation in two experimental disease models. In human CD1a transgenic mice, the toll-like receptor (TLR)7 agonist imiquimod induces more pronounced splenomegaly, expansion of the peripheral blood and spleen T cell compartments, and enhanced neutrophil and eosinophil responses compared to the wild-type, accompanied by elevated skin and plasma cytokine levels, including IL-23, IL-1α, IL-1β, MCP-1 and IL-17A. Similar systemic escalation is shown in MC903-induced skin inflammation. The exacerbated inflammation could be counter-acted by CD1a-blocking antibodies, developed and screened in our laboratories. The beneficial effect is epitope dependent, and we further characterise the five best-performing antibodies for their capacity to modulate CD1a-expressing cells and ameliorate CD1a-dependent systemic inflammatory responses. In summary, we show that a therapeutically targetable CD1a-dependent pathway may play a role in the systemic spread of cutaneous inflammation.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Additional Information: License information from Publisher: LICENSE 1: URL: http://creativecommons.org/licenses/by/4.0/, Type: open-access
Publisher: Nature Research
ISSN: 2041-1723
Date of First Compliant Deposit: 8 December 2022
Date of Acceptance: 17 November 2022
Last Modified: 11 Oct 2023 19:40
URI: https://orca.cardiff.ac.uk/id/eprint/154746

Citation Data

Cited 6 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics